Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  BioMarin Pharmaceutical Inc.    BMRN   US09061G1013

Delayed Quote. Delayed Nasdaq - 04/24 04:00:00 pm
120.28 USD   -2.17%
04/23 BioMarin Presents Data on Duchenne Muscular Dystrophy at the 67th..
04/21 BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASD..
04/14 BIOMARIN TO HOS : 30pm ET
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo BioMarin Pharmaceutical In
Discovers, develops and commercializes innovative pharmaceuticals for serious diseases & medical conditions

BioMarin Pharmaceutical, Inc. develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions.

The company operates its business through one segment, the biopharmaceutical development and commercialization segment.

Its company's product portfolio is comprised of five approved products and multiple investigational product candidates which include Naglazyme, Kuvan, Aldurazyme, Firdapse and VIMIZIM.

Naglazyme is a recombinant form of N-acetylgalactosamine 4-sulfatase indicated for patients with ucopolysaccharidosis VI. MPS VI is a debilitating life-threatening genetic disease for which no other drug treatment currently exists and is caused by the deficiency of arylsulfatase B, an enzyme normally required for the breakdown of certain complex carbohydrates known as glycosaminoglycans, or GAGs.

Kuvan is a proprietary synthetic oral form of 6R-BH4, a naturally occurring enzyme co-factor for phenylalanine hydroxylase, indicated for patients with PKU, which is an inherited metabolic disease that affects patients under the age of 40 in the developed world.

Aldurazyme has been approved for marketing in the U.S., EU and other countries for patients with mucopolysaccharidosis.

Firdapse is a form of 3, 4-diaminopyridine for the treatment of Lambert Myasthenic Syndrome.

And VIMIZIM is an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder.

The company was founded on March 21, 1997 and is headquartered in Novato, CA.

Number of employees : 1 681 persons.
Sales per Businesses
20132014Delta
USD (in Million)%USD (in Million)%
Biopharmaceutical Development and Commercialization548.49100%751.04100.1% +26.97%
Sales per Regions
20132014Delta
USD (in Million)%USD (in Million)%
United States277.5050.6%380.0450.7% +26.98%
Europe116.9021.3%139.9418.7% +16.47%
Rest of World76.6314%112.4915% +31.88%
Latin America67.3412.3%118.5615.8% +43.2%
Managers
NameAgeSinceTitle
Jean-Jacques Bienaimé612005Chief Executive Officer & Director
Pierre LaPalme742004Chairman
Daniel K. Spiegelman, MBA552012Chief Financial Officer & Executive Vice President
Robert A. Baffi PhD, MBA592000Executive Vice President-Technical Operations
Gordon Vehar, PhD-2008Vice President-Research
Henry J. Fuchs, MD562009Chief Medical Officer & Executive Vice President
Eduardo E. Von Pervieux, MBA-2008Chief Information Officer & Vice President
Elaine J. Heron PhD, MBA672002Independent Non-Executive Director
Mike G. Grey622005Independent Non-Executive Director
Richard A. Meier552006Independent Non-Executive Director
Shareholders
NameShares%
Capital Research & Management Co. (Global Investors) 18,064,529 11.4%
Sands Capital Management LLC 12,183,113 7.66%
Fidelity Management & Research Co. 10,407,523 6.54%
The Vanguard Group, Inc. 8,848,001 5.56%
PRIMECAP Management Co. 8,016,518 5.04%
BlackRock Fund Advisors 6,477,085 4.07%
Jennison Associates LLC 5,660,987 3.56%
Baker Bros. Advisors LP 3,713,950 2.33%
William Blair & Co. LLC (Investment Management) 2,702,589 1.70%
SSgA Funds Management, Inc. 2,655,618 1.67%
Holdings
NameShares%Valuation
Catalyst Pharmaceutical Partners, Inc. (CPRX) 6,666,6678.19%28,866,668 USD
Sector
Healthcare
Pharmaceuticals & Medical Research
 Pharmaceuticals
  Pharmaceuticals
   Generic Pharmaceuticals
Advertisement
Sector Pharmaceuticals
Growth (Revenue) Profitability
SUN PHARMACEUTICA..
BIOMARIN PHARMACE..
OTSUKA HOLDINGS C..
ENDO INTERNATIONA..
HOSPIRA, INC.
ASPEN PHARMACARE ..
ONO PHARMACEUTICA..
SHANGHAI FOSUN PH..
CIPLA LTD
TAISHO PHARMACEUT..
SIHUAN PHARMACEUT..
CADILA HEALTHCARE..
SHENZHEN HEPALINK..
-
SICHUAN KELUN PHA..
XIZANG HAISCO PHA..
LUYE PHARMA GROUP..
-
ZHEJIANG CONBA PH..
HYBIO PHARMACEUTI..
CHINA MEDICAL SYS..
HUAPONT-NUTRICHEM..
Sector Pharmaceuticals
BioMarin Pharmaceutical In : Connections
Selventa, Inc.
Rapidscan Pharma Solutions, Inc.
Pediapharm Inc
Biotechnology Industry Organization
Ziarco Group Ltd.
A. M. Pappas & Associates LLC
Ziarco Pharma Ltd.
Algorithme Pharma, Inc.
GLyPharma Therapeutic, Inc.
Reneo Pharmaceuticals, Inc.
Balance Therapeutics, Inc.
Zephyrus Biosciences, Inc.
Aerogen, Inc.
Amplyx Pharmaceuticals, Inc.
Company contact information
BioMarin Pharmaceutical, Inc.
770 Lindaro Street
San Rafael, CA 94901

Phone : +1.415.506.6700
Fax : +1.415.382.7889
Web : www.bmrn.com
© 2015 People , Fundamentals and Ownership   
Dynamic quotes  
ON
| OFF